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Abstract
Until recently, treatment of Clostridium difﬁcile infection (CDI) was mainly limited to oral metronidazole and vancomycin, neither of
which is optimal. Up to 25% of patients with CDI experience recurrence of infection within 30 days following treatment with these
agents, while c. 45–65% of these patients experience further (and sometimes multiple) recurrences. Recurrent CDI represents a major
treatment challenge for which new therapeutic options are sorely needed. Fidaxomicin is a ﬁrst-in-class, oral macrocyclic antibiotic with
targeted bactericidal activity against C. difﬁcile and minimal effect on the constituents of the normal colonic microﬂora. This microﬂora-
sparing activity allows for more rapid restoration of the normal colonic microﬂora in patients with CDI. In two separate, but almost
identical, phase 3 clinical trials in which patients with CDI were treated with either ﬁdaxomicin or vancomycin, ﬁdaxomicin demon-
strated superior clinical outcomes in comparison with the current best available treatment. While non-inferiority was demonstrated
with respect to rates of clinical cure at end of treatment, signiﬁcantly fewer ﬁdaxomicin-treated patients experienced disease recur-
rence, which translated into clinically signiﬁcant improvements in sustained clinical cure. Subsequent sub-population analyses suggest that
these beneﬁts extend to older patients, patients with severe CDI, renally impaired patients and patients with a prior episode of CDI.
For CDI patients receiving concomitant antibiotics, ﬁdaxomicin achieved signiﬁcantly better rates of clinical cure and sustained clinical
cure than vancomycin recipients. Fidaxomicin has a safety proﬁle similar to oral vancomycin and appears generally well tolerated. Fidax-
omicin represents an important addition to current treatment options for CDI.
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Introduction
In patients with Clostridium difﬁcile infection (CDI), the aim
of treatment is to achieve rapid resolution of symptoms
together with restoration of the normal colonic microﬂora
and normalization of bowel function. Cessation of the anti-
bacterial therapy associated with the onset of CDI is
usually the ﬁrst step and may be effective in a minority of
patients [1]. However, this approach is feasible for only a
small number of patients with very mild disease who
do not need to continue taking antibiotic therapy for a
concurrent systemic infection. In addition, because it is difﬁ-
cult to predict which patients will clear the infection spon-
taneously following cessation of antibiotic therapy, and
because delays to treatment may result in clinical deteriora-
tion, most patients with CDI need speciﬁc antibacterial
therapy to treat C. difﬁcile.
Although there have been attempts to develop non-anti-
bacterial therapies for CDI, none has yet demonstrated
superior clinical effectiveness [2]. Today, we are still essen-
tially dependent on two antibiotics (metronidazole and
vancomycin) for the treatment of CDI. However, there are
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shortcomings with both agents and, consequently, a need
exists for new, more effective CDI therapies that will not
only treat an initial episode of the disease but, more
importantly, reduce the risk of recurrence.
Of the new and emerging treatment options for the man-
agement of CDI, several of which are listed in Table 1 from
reviews on the topic [2–4], this article focuses on ﬁdaxomi-
cin, a novel oral macrocyclic antibiotic that has recently been
licensed for the treatment of CDI.
Current Treatment Regimens for CDI
In use for more than 30 years, oral metronidazole and oral
vancomycin continue to underpin the treatment of CDI.
Both antibiotics show similar rates of clinical cure in patients
with initial or recurrent mild-to-moderate CDI, while higher
cure rates have been reported with vancomycin in patients
with initial or recurrent severe CDI [5]. Current guidelines
from the European Society for Clinical Microbiology and
Infectious Diseases (ESCMID) reﬂect these differences, with
oral metronidazole being recommended for patients with
non-severe CDI and oral vancomycin for severe CDI [2].
For patients who experience second and subsequent recur-
rences of CDI (i.e. a third episode and beyond), ESCMID
recommends treatment with vancomycin for a severe ﬁrst
recurrence with the option of using tapered or pulsed (inter-
mittent) dosing regimens. The aim of tapered or pulsed ther-
apy is to eradicate any vegetative C. difﬁcile cells that have
germinated from spores since the last antibiotic exposure
[6]. In addition, tapered or pulsed dosing may suppress C.
difﬁcile growth, thus enabling the normal colonic microﬂora
to recover [7]. Despite these varied treatment regimens,
signiﬁcant numbers of patients experience recurrent CDI,
including multiple recurrences, following treatment with
either metronidazole or vancomycin. In fact, ESCMID has
identiﬁed recurrent CDI as the biggest treatment challenge
we face today in managing patients with CDI [2].
Shortcomings of Current Antibacterial
Therapy for CDI
Failure to prevent CDI from recurring following successful
treatment of an initial episode is common with both metro-
nidazole and vancomycin. Up to 25% of CDI patients experi-
ence recurrent CDI within 30 days following treatment with
these antibiotics [8,9], while c. 45–65% of these patients
experience further (and sometimes multiple) recurrences
[7,10]. Rates of recurrent CDI appear to have increased with
both antibiotics in the last decade, as shown in the review
by Aslam et al. [11]. At the same time, there has been grow-
ing concern about the declining efﬁcacy of metronidazole. A
review of studies published between 1966 and 2005 showed
that rates of treatment failure increased dramatically from
about 3% before 2000 to an average of 18% (range 16–38%)
from 2000 onwards [11]. Although there have been reports
of strains of C. difﬁcile with reduced susceptibility to metroni-
dazole [12], treatment failure has not been directly associ-
ated with drug resistance [13]. It is possible that reduced
susceptibility and the poor pharmacokinetic properties of
oral metronidazole, which result in very low intracolonic
drug levels, may together account for rising rates of treat-
ment failures [14]. Recent evidence also suggests that
TABLE 1. New treatments and investigational approaches for CDI [2–4]
Product or
compound Description Development status for CDI
Fidaxomicin Macrocyclic antibiotic European Medicines Agency (EMA) and US Food and Drug Administration
(FDA) approved therapy
Rifaximin Rifamycin derivative indicated for travellers’ diarrhoea Off-label use in recurrent CDI. Pilot studies in metronidazole-refractory CDI
Nitazoxanide Thiazolide anti-parasitic antibiotic Small clinical trials demonstrated similar efﬁcacy to metronidazole but were too
small to demonstrate non-inferiority to vancomycin
Tigecycline Broad-spectrum glycylcycline antibiotic Case studies
Ramoplanin Narrow-spectrum, Gram-positive glycolipodepsipeptide antibiotic Phase 3
Cadazolid Hybrid oxazolidinone–quinolone antibiotic Phase 2 (NCT01222702)a
CB-183,315 Narrow-spectrum, Gram-positive lipopeptide antibiotic Phase 3 planned 2012b
CDA1 and CDB1 Fully human monoclonal antibodies to C. difﬁcile toxins A and B Phase 3 for prevention of C. difﬁcile infection (CDI) recurrence (MODIFY I
[NCT01241552]c and MODIFY II [NCT01513239])e
ACAM-CDIFF Active C. difﬁcile toxoid vaccine Phase 2 placebo-controlled for primary CDI prevention (NCT00772343)e
VP 20621 Non-toxigenic C. difﬁcile Phase 2 for prevention of CDI recurrence (NCT01259726)f
Faecal microbiota
therapy
Infusion of faeces from healthy donor Case series and case studies
ahttp://clinicaltrials.gov/ct2/show/NCT01222702.
bhttp://clinicaltrials.gov/ct2/show/NCT01597505?term=CB-183%2C315&rank=2.
chttp://clinicaltrials.gov/ct2/show/NCT01241552.
dhttp://clinicaltrials.gov/ct2/show/NCT01513239.
ehttp://clinicaltrials.gov/ct2/show/NCT00772343.
fhttp://clinicaltrials.gov/ct2/show/NCT01259726.
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outcomes may be further impaired if patients receive a stan-
dard regimen of intravenous metronidazole as an alternative
to oral metronidazole or oral vancomycin [15]. In this hospi-
tal-based, cohort study, mortality within 30 days of the start
of treatment was signiﬁcantly higher in the intravenous met-
ronidazole arm compared with patients on oral metronida-
zole or oral vancomycin (38.1% vs. 7.4% and 9.5%,
respectively, p <0.001) [15].
Oral fusidic acid and the non-absorbable rifamycin, rifaxi-
min, are among other antibiotics that are sometimes used in
the treatment of CDI (reviewed in [2]). However, fusidic
acid is considered less effective than oral metronidazole or
vancomycin, while concerns have been raised about the
development of resistance to rifaximin among strains of
C. difﬁcile [2]. Recent data suggest that resistance to rifaxi-
min, an antibiotic commonly used in some European hospi-
tals for CDI, may be as high as 26% for isolates of the
hypervirulent 027 ribotype of C. difﬁcile [16].
Recurrent CDI can be due to either a relapse of the origi-
nal infection or to re-infection with a different strain of CDI.
Certain patients appear to be at increased risk of recurrent
CDI, including those who are immunocompromised [17],
those on concomitant antibiotics [2,18–21], those who are
renally impaired (Bauer et al., 2011, 21st European Congress
of Clinical Microbiology and Infectious Diseases (ECCMID)/
27th International Congress of Chemotherapy (ICC),
Abstract LB2771) and those aged 65 years and older [19–21].
Current antibiotics for CDI have several limitations, chief
of which is unacceptably high rates of disease recurrence.
New treatments that signiﬁcantly reduce recurrence rates
would represent an important therapeutic advance for
patients with CDI.
Fidaxomicin as a New Treatment Option
for CDI
Among antibiotics in development for CDI, ﬁdaxomicin has
attracted particular interest. The ﬁrst member of a new class
of antibiotics called macrocycles, ﬁdaxomicin has a number
of properties that appear ideally suited to the treatment of
CDI. Unlike current antibiotics used for CDI, ﬁdaxomicin
displays targeted bactericidal activity against C. difﬁcile [22]
and has minimal effect on the constituents of the normal
colonic microﬂora, including Bacteroides spp. [23,24]. This mi-
croﬂora-sparing activity may allow for more rapid restora-
tion of the commensal microﬂora in the colon of patients
with CDI and may reduce the risk of further colonization
and overgrowth with C. difﬁcile [24]. Against C. difﬁcile, and in
contrast to metronidazole and vancomycin, ﬁdaxomicin also
has a long post-antibiotic effect [25]. This means it has
potential to maintain antibacterial activity to a certain degree
even when the concentration has fallen below the minimum
inhibitory concentration. This could be beneﬁcial in CDI, a
disease in which rapid intestinal transit due to diarrhoea may
hasten faecal drug elimination.
Fidaxomicin inhibits RNA polymerase activity of Gram-
positive bacteria at a very early stage of transcription [26].
Because it blocks gene transcription it has potential to inhibit
the expression of genes responsible for sporulation and
toxin production. Studies have shown that ﬁdaxomicin (and
its active metabolite) inhibits C. difﬁcile sporulation, in con-
trast to vancomycin, metronidazole and rifaximin, which have
no inhibitory effect on the sporulation process (Gomez et al.,
Interscience Conference on Antimicrobial Agents and Che-
motherapy, 2011, Abstract C1-632). Fidaxomicin also inhibits
C. difﬁcile toxin production (Sims et al., Interscience Confer-
ence on Antimicrobial Agents and Chemotherapy, 2011,
Abstract C1-634).
Although there is debate surrounding the relative impor-
tance of metronidazole and vancomycin in promoting acquisi-
tion of vancomycin-resistant enterococci (VRE) [27],
antibiotics with reduced likelihood of promoting VRE may be
beneﬁcial. Compared with vancomycin, ﬁdaxomicin demon-
strated a signiﬁcantly lower risk of acquisition of VRE among
CDI patients with negative VRE stool samples at enrolment
in the phase 3 registration trials [28].
The antibacterial properties of ﬁdaxomicin are comple-
mented by pharmacokinetic properties that are suited to
treatment of an infection localized to the gut. These include
very low systemic absorption following oral administration
and correspondingly high intracolonic concentrations and an
attendant low risk of systemic adverse effects [29]. Fidaxomi-
cin undergoes esterase-dependent metabolism [26] to a
microbiologically active metabolite [22]; non-cytochrome
P450 (CYP)-mediated metabolism means there is a low risk
of interaction with co-administered drugs [26]. Finally, ﬁdax-
omicin has demonstrated a low propensity for resistance
development and cross-resistance with other major classes
of antibiotics [28].
Subsequent phase 3 clinical trials of ﬁdaxomicin in more
than 1000 patients with CDI have shown that its microbio-
logical and pharmacokinetic attributes translate into signiﬁ-
cant clinical beneﬁts [9,30]. In two separate, but almost
identical, randomized, double-blind trials, in which patients
with conﬁrmed CDI received either 200 mg oral ﬁdaxomicin
twice daily or 125 mg oral vancomycin four times daily for
10 days, rates of clinical cure in both the modiﬁed intent-to-
treat (mITT) and per protocol (PP) populations were similar
at end of therapy in both treatment arms (Fig. 1). Time to
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resolution of diarrhoea was also similar in both treatment
arms. The trials thus met the primary efﬁcacy endpoint of
non-inferiority to vancomycin in clinical cure at end of treat-
ment in both analysis populations. However, ﬁdaxomicin
achieved signiﬁcantly lower rates of recurrence of CDI (no
recurrence within 30 days of cessation of therapy) compared
with vancomycin. In the mITT and PP populations of the
North American trial (study 003), the reduction in recur-
rence achieved with ﬁdaxomicin compared with vancomycin
was 9.9% (p 0.005) and 10.7% (p 0.004), respectively [9].
Corresponding differences in the mITT and PP populations
in the North American and European trial (study 004) were
14.2% (p 0.0002) and 12.5% (p 0.002), respectively [30]. This
led to signiﬁcantly higher rates of sustained clinical cure,
deﬁned as clinical cure without recurrence of diarrhoea dur-
ing the 30-day follow-up period, in the ﬁdaxomicin vs. the
vancomycin treatment arms (Fig. 2). Across the two trials,
75.5% and 78.6% of ﬁdaxomicin-treated patients in the mITT
and PP populations, respectively, achieved a sustained clinical
cure compared with 63.8% and 66.4% of vancomycin recipi-
ents, respectively [26].
A subsequent meta-analysis of the two trials has both con-
ﬁrmed and augmented the ﬁnding that ﬁdaxomicin is supe-
rior to oral vancomycin in reducing CDI recurrences [31].
Based on an intent-to-treat (ITT) analysis of pooled data, the
post-hoc, exploratory time-to-event investigation showed
that in comparison with oral vancomycin, treatment with ﬁ-
daxomicin was associated with an overall 40% reduction in
FIG. 1. Rates of clinical cure at end of treatment (primary efﬁcacy endpoint) in the ﬁdaxomicin phase 3 trials (studies 003 and 004) [9,30]. ns,
non-signiﬁcant. Patients in the modiﬁed intent-to-treat (mITT) population underwent randomization and received ‡1 dose of study medication.
Patients in the per protocol population comprised those in the mITT population who received ‡3 days of study medication (in cases of failure)
or ‡8 days (in cases of clinical cure) with documented adherence to study protocol and who underwent end-of-treatment evaluation. Reprinted
from Cornely et al. [30], copyright (2012), with permission from Elsevier. Reproduced with permission from Louie et al. [9], copyright Massachu-
setts Medical Society.
FIG. 2. Rates of sustained clinical cure (clinical cure without recurrence of diarrhoea during the 30-day follow-up period) in the ﬁdaxomicin
phase 3 trials (studies 003 and 004) [9,30]. Patients in the modiﬁed intent-to-treat (mITT) population underwent randomization and received ‡1
dose of study medication. Patients in the per protocol population comprised those in the mITT population who received ‡3 days of study medi-
cation (in cases of failure) or ‡8 days (in cases of clinical cure) with documented adherence to study protocol and who underwent end-of-treat-
ment evaluation. Reprinted from Cornely et al. [30], copyright (2012), with permission from Elsevier. Reproduced with permission from Louie
et al. [9], copyright Massachusetts Medical Society.
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persistent diarrhoea, recurrence of CDI or death during the
40-day follow-up period (p <0.0001) [31]. Thus, as the
authors of this study concluded, ﬁdaxomicin has the potential
to greatly improve outcome in patients with CDI of mild-to-
moderate severity.
Fidaxomicin: Efﬁcacy in Patients at
Increased Risk of CDI Recurrence
Within the CDI population, certain patients are at increased
risk of recurrence. To this end, separate, prespeciﬁed efﬁ-
cacy analyses were carried out on key subgroups within the
population of patients enrolled in the ﬁdaxomicin phase 3
registration trials. These subgroups included older patients,
those with severe CDI, patients infected with the hyperviru-
lent 027 strain of C. difﬁcile, patients receiving concomitant
antibiotic therapy, patients who had experienced a prior epi-
sode of CDI and patients with renal impairment. Table 2
summarizes rates of CDI recurrence by treatment arm and
subgroup in the North American trial (study 003) [9] and
North American and European trial (study 004) [30].
Among the older cohort of patients enrolled in the two
trials, almost a third of whom were aged 75 years or older,
rates of clinical cure were similar between treatment arms.
However, and consistent with the results for the whole
study population, signiﬁcantly lower rates of recurrence and
superior rates of sustained clinical cure were seen in the ﬁ-
daxomicin treatment arm in the older age groups. Similar
results were seen with respect to the subgroup of patients
with severe CDI, broadly deﬁned in relation to current ESC-
MID severity criteria [2]. Again, treatment with ﬁdaxomicin
provided comparable efﬁcacy to vancomycin but with the
added beneﬁt of a lower risk of disease recurrence and a
corresponding, superior sustained clinical response [9, 30].
Across the two trials, approximately one-third of patients
were infected with the hypervirulent 027 strain of C. difﬁcile,
with most cases arising in North America rather than in Eur-
ope where prevalence of the 027 ribotype appears lower. A
comparison of outcomes based on pooled data from the two
treatment arms showed no signiﬁcant difference in clinical
cure rates, suggesting that ﬁdaxomicin is as effective as vanco-
mycin in these more difﬁcult-to-treat patients. There was no
signiﬁcant difference in recurrence rates between treatments
in patients with infections due to the hypervirulent 027 strain
of C. difﬁcile; however, in the non-027 group recurrence rates
were signiﬁcantly lower in ﬁdaxomicin-treated patients com-
pared with vancomycin recipients (8.4% vs. 25.3%, respec-
tively; p <0.001) [32]. Treatment with ﬁdaxomicin was also
superior to vancomycin in the subgroup of patients who
experienced a prior episode of CDI within 3 months before
entering the phase 3 trial [33]. Of the 128 patients from the
two trials who were evaluable for a second recurrence (third
episode), 22 vancomycin-treated patients (35.5%) experi-
enced a further recurrence within 30 days compared with 13
(19.7%) of those treated with ﬁdaxomicin (p 0.045).
Clostridium difﬁcile infection typically occurs in hospitalized
patients who have been treated with broad-spectrum antibi-
otics and yet for many of these patients discontinuing antibi-
otic therapy is not an option. In the phase 3 trials, 275
(27.5%) patients in total received concomitant antibacterial
therapy for other infections during the 10-day course of
treatment for CDI or in the 30-day follow-up period. In
patients receiving concomitant antibacterial therapy, rates of
clinical cure based on pooled data were signiﬁcantly higher in
patients treated with ﬁdaxomicin compared with vancomycin
recipients (90.0% vs. 79.4%, respectively; p 0.04) and rates of
recurrence based on pooled data were signiﬁcantly lower
(16.9% vs. 29.2%, respectively; p 0.048) [34].
Patients with chronic renal disease are considered to be
at increased risk of contracting CDI and often have a poorer
prognosis than those with normal renal function [35]. In the
phase 3 trials, 57% of patients had abnormal renal function at
baseline, of which almost a third had moderate-to-severe
renal impairment. Consistent with results for the study pop-
ulation as a whole, rates of clinical cure were similar in the
two treatment arms for each level of renal impairment, albeit
lower in patients with severe renal impairment. Treatment
TABLE 2. Rates of CDI recurrence
in prespeciﬁed subgroups of CDI
patients treated with either ﬁdax-
omicin or vancomycinSubgroup
North American trial
(study 003) [9]
North American and European
trial (study 004) [30]
Fidaxomicin
n/N (%)
Vancomycin
n/N (%)
Fidaxomicin
n/N (%)
Vancomycin
n/N (%)
Age ‡65 years 20/103 (19.4) 40/131 (30.5) 16/121 (13.2) 30/108 (27.8)
Severe CDI 12/92 (13.0) 29/109 (26.6) 4/48 (8.3) 14/43 (32.6)
Ribotype 027 16/59 (27.1) 14/67 (20.9) 12/54 (22.2) 19/50 (38.0)
Non-027 strain 12/117 (10.3) 34/121 (28.1) 11/120 (9.2) 29/106 (27.4)
Concomitant antibiotics 14/81 (17.3) 25/90 (27.8) 13/74 (17.6) 12/55 (21.8)
Data from modiﬁed intent-to-treat populations.
CDI, C. difﬁcile infection.
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with ﬁdaxomicin was, however, superior in reducing the risk
of CDI recurrence at all levels of renal function (p <0.05). In
patients with normal renal function there was an absolute
10% difference in recurrence rates between ﬁdaxomicin and
vancomycin (11% vs. 21%, respectively) but this increased to
21% in patients with severe renal impairment (15% vs. 35%,
respectively; Mullane et al., Annual Congress of the Infectious
Diseases Society of America, 2011, Abstract), suggesting that
ﬁdaxomicin may be of particular beneﬁt in this vulnerable
patient subgroup.
Although a broad spectrum of CDI patients were enrolled
in the ﬁdaxomicin clinical trial programme, thus reﬂecting
many patients seen in routine clinical practice, patients with
CDI concurrent with inﬂammatory bowel disease or those
with life-threatening or fulminant CDI (including toxic mega-
colon) were not eligible for inclusion in the trials [9, supple-
ment to 30]. Patients with extremely severe CDI may have
paralytic ileus and there is no consensus on how best to
treat such cases [2]. As an orally administered antibiotic, ﬁ-
daxomicin is not suitable for CDI patients who need paren-
teral therapy. In addition, only adult patients were enrolled
in the phase 3 trials of ﬁdaxomicin and data are not there-
fore available on the use of ﬁdaxomicin in paediatric patients,
while only limited data are available to date on its use in im-
munosuppressed patients.
Safety and Tolerability Proﬁles of
Metronidazole, Vancomycin and
Fidaxomicin
With respect to the safety and tolerability of antibiotics used
in the treatment of CDI, oral vancomycin is considered to
have an improved side-effect proﬁle compared with metroni-
dazole, which derives from differences in their pharmacoki-
netics [14]. Oral vancomycin is not absorbed and serum
levels are correspondingly very low. Oral metronidazole is
almost completely absorbed even in the presence of diar-
rhoea and is completely absorbed in the normal gut [1,36].
In fact, intracolonic concentrations of metronidazole appear
similar whether the drug is given orally or intravenously to
patients with diarrhoea [36]. Irrespective of route of admin-
istration, patients receiving metronidazole are at risk of
developing systemic adverse events [37].
Fidaxomicin undergoes minimal systemic absorption
[28,29] and is similar to oral vancomycin in this respect.
Thus, it would be expected to have a generally similar tolera-
bility proﬁle and this is borne out in practice. In its phase 3
clinical trials, rates of treatment-emergent adverse events
(TEAEs), study drug-related TEAEs, serious TEAEs and all-
cause mortality were generally similar for ﬁdaxomicin and
vancomycin (Table 3).
Investigational Approaches for CDI and
Recurrent CDI
Fidaxomicin represents an important addition to current
treatment options for CDI and should help in the manage-
ment of patients at increased risk of recurrent disease.
Among other approaches being investigated with potential to
address current treatment gaps two non-antibiotic therapies
are of interest: faecal microbiota transplantation (FMT) and
immunotherapy with speciﬁc anti-toxin antibodies to C. difﬁ-
cile. Both are designed to enhance host protection against
CDI, the ﬁrst by restoring colonization resistance and the
second by supplementing deﬁciencies in the patient’s adaptive
immune response to C. difﬁcile.
Most evidence for the beneﬁt of FMT, in which donor fae-
ces from a healthy individual are transplanted into the colon
of a CDI patient, as a treatment for multiple-recurrent CDI
has come from single-centre case series and case studies and
is based on small numbers of patients [38]. However, a
recent report from a multicentre, long-term follow-up study
in a much larger number of patients (n = 77) who received
FMT for refractory CDI has also shown encouraging results,
with 74% of patients experiencing a resolution of diarrhoea
within 3 days of treatment [38]. Given practical consider-
ations related to material preparation and administration of
donor faeces, as well as aesthetic concerns and potential
risks of transmitting pathogens, for the time being FMT is
likely to remain a reserve therapy for patients who experi-
ence multiple recurrences and for whom other treatments
have failed.
Failure to mount an effective immunoglobulin (Ig)G-medi-
ated antibody response to C. difﬁcile toxins differentiates
patients with CDI from those asymptomatically colonized
with C. difﬁcile [39]. Passive immunotherapy, in which
TABLE 3. Frequency of treatment-emergent adverse events
in patients treated with ﬁdaxomicin or vancomycin in the
phase 3 trials (pooled data)
Type of event, n (%)
Fidaxomicin
N = 564
Vancomycin
N = 583
Any TEAE 373 (66.1)a 372 (63.8)a
Study drug-related TEAE 60 (10.6)b 65 (11.1)b
Discontinuation due to TEAE 45 (8.0)b 49 (8.4)b
Serious TEAE 145 (25.7)a 135 (23.3)a
All-cause mortality 36 (6.4)a 38 (6.5)a
TEAE, treatment-emergent adverse events.
aRef. [26].
bRef. [28].
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patients receive an infusion of antibodies speciﬁc to C. difﬁcile
toxins, aims to aid patients who have failed to increase their
adaptive immune response to C. difﬁcile toxins. Although data
are still limited, a phase 2 trial of infused human monoclonal
antibodies against C. difﬁcile toxins A and B suggests they
may have protective efﬁcacy and help reduce the frequency
of recurrence when given as an adjunct to conventional anti-
biotic therapy [8]. In a trial involving 200 patients with CDI,
a substantial reduction in recurrence was observed in
patients who received neutralizing anti-toxin monoclonal
antibody therapy in addition to metronidazole or vancomycin
compared with those who received conventional antibiotic
therapy alone (7% vs. 25%, respectively; p <0.001) [8].
FMT and passive immunotherapy are still investigational
therapies and common to both is a need for large-scale ran-
domized controlled trials to comprehensively evaluate their
efﬁcacy and safety. Following successful completion of the
phase 2 trial of passive immunotherapy (NCT00350298) [8],
patients are now being recruited for phase 3 trials (MODIFY
I [NCT01241552]; MODIFY II [NCT01513239]), which are
designed to investigate whether passive immunotherapy in
addition to standard of care antibiotic therapy will decrease
CDI recurrence.
How will New Treatments Alleviate the
Burden of CDI?
Although most patients with CDI respond to an initial 10-
day course of either oral metronidazole or vancomycin,
when used again for recurrent CDI these treatments tend to
fail repeatedly because they do not help restore normal col-
onization resistance [40]. In fact, prolonged use of antibiotics
to treat recurrent CDI probably contributes to continued
disturbance of the normal colonic microﬂora and further
delays the re-establishment of colonization resistance [40].
At present there is uncertainty about how best to treat
patients with recurrent CDI and especially those who expe-
rience multiple recurrences. Data presented here suggest
that by reducing the risk of recurrence following either a
ﬁrst episode or ﬁrst recurrence (second episode), use of ﬁ-
daxomicin may help address this problem and improve out-
comes in patients with CDI in comparison with vancomycin.
Reducing the risk of CDI recurrence has the potential to be
of beneﬁt not only to patients in terms of reduced morbidity
and mortality, with concomitant improvements in quality of
life, but also to the healthcare system by eliminating the
costs of treating additional episodes of CDI and the need for
prolonged patient isolation, as well as reducing the risk of
person-to-person transmission.
In current treatment guidelines for CDI, choice of ﬁrst-
line therapy is governed by disease severity, which ESCMID
deﬁnes as an episode of CDI accompanied by one or more
signs of severe colitis [2]. These include fever, rigors, haemo-
dynamic instability, marked leucocytosis, elevated serum cre-
atinine or lactate, pseudomembranous colitis, intestinal
distension, colonic wall thickening, pericolonic fat stranding
and ascites not attributable to any other cause [2]. With the
approval of new antibiotics, such as ﬁdaxomicin, and other
non-antibiotic treatments on the horizon, future guidelines
will likely give equal emphasis to reducing the risk of CDI
recurrence in treatment decisions, especially in those sub-
groups that are at greatest risk of experiencing recurrence.
Acknowledgements
The author wishes to thank Elements Communications Ltd
(Westerham, UK) for medical writing assistance, funded by
Astellas Pharma Europe Ltd (Staines, UK).
Provenance
The development of the content and the printing of this sup-
plement has been funded by Astellas Pharma Europe Ltd.
This supplement was created in collaboration with the faculty
from the Astellas-sponsored symposium at the 2012 ECC-
MID Congress.
Transparency Declaration
Oliver A Cornely is supported by the German Federal Ministry
of Research and Education (BMBF grant 01KN1106). Oliver A
Cornely has received grant/research support from Actelion,
Astellas, Basilea, Bayer, BioCryst, Celgene, F2G, Genzyme, Gi-
lead, Merck/Schering, Miltenyi, Optimer, Pﬁzer, Quintiles and
ViroPharma. Oliver A Cornely has worked as a consultant for
Astellas, Basilea, F2G, Gilead, Merck/Schering, Optimer, Pﬁzer
and Sanoﬁ Pasteur and has participated in speakers’ bureaux
for Astellas, Gilead, Merck/Schering and Pﬁzer.
References
1. Bartlett JG. The case for vancomycin as the preferred drug for treat-
ment of Clostridium difﬁcile infection. Clin Infect Dis 2008; 46: 1489–
1492.
2. Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical
Microbiology and Infectious Diseases (ESCMID): treatment guidance
34 Clinical Microbiology and Infection, Volume 18, Supplement 6, December 2012 CMI
ª2012 The Author
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18 (Suppl. 6), 28–35
document for Clostridium difﬁcile infection (CDI). Clin Microbiol Infect
2009; 15: 1067–1079.
3. Hedge DD, Strain JD, Heins JR, Farver DK. New advances in the
treatment of Clostridium difﬁcile infection (CDI). Ther Clin Risk Manag
2008; 4: 949–964.
4. Koo HL, Garey KW, DuPont HL. Future novel therapeutic agents
for Clostridium difﬁcile infection. Expert Opin Investig Drugs 2010; 19:
825–836.
5. Zar FA, Bakkanagari SR, Moorthi SR, Davis MB. A comparison of
vancomycin and metronidazole for the treatment of Clostridium difﬁ-
cile-associated diarrhea, stratiﬁed by disease severity. Clin Infect Dis
2007; 45: 302–307.
6. Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difﬁ-
cile infection. Clin Infect Dis 2008; 46 (Suppl 1): S32–S42.
7. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treat-
ment strategies for 163 cases of recurrent Clostridium difﬁcile disease.
Am J Gastroenterol 2002; 97: 1769–1775.
8. Lowy I, Molrine DC, Leav BA et al. Treatment with monoclonal
antibodies against Clostridium difﬁcile toxins. N Engl J Med 2010; 362:
197–205.
9. Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomy-
cin for Clostridium difﬁcile infection. N Engl J Med 2011; 364: 422–431.
10. McFarland LV, Surawicz CM, Greenberg RN et al. A randomized pla-
cebo-controlled trial of Saccharomyces boulardii in combination with
standard antibiotics for Clostridium difﬁcile disease. JAMA 1994; 271:
1913–1918.
11. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difﬁcile-
associated disease: old therapies and new strategies. Lancet Infect Dis
2005; 5: 549–557.
12. Baines SD, O’Connor R, Freeman J et al. Emergence of reduced sus-
ceptibility to metronidazole in Clostridium difﬁcile. J Antimicrob Chemo-
ther 2008; 62: 1046–1052.
13. Rupnik M, Wilcox MH, Gerding DN. Clostridium difﬁcile infection: new
developments in epidemiology and pathogenesis. Nature Rev Microbiol
2009; 7: 526–536.
14. DuPont HL. The search for effective treatment of Clostridium difﬁcile
infection. N Engl J Med 2011; 364: 473–474.
15. Wenisch JM, Schmid D, Kuo HW et al. Prospective observational
study comparing three different treatment regimens in patients with
Clostridium difﬁcile infection. Antimicrob Agents Chemother 2012; 56:
1974–1978.
16. Huhulescu S, Sagel U, Fiedler A et al. Rifaximin disc diffusion test for
in vitro susceptibility testing of Clostridium difﬁcile. J Med Microbiol
2011; 60: 1206–1212.
17. Cohen MB. Clostridium difﬁcile infections: emerging epidemiology and
new treatments. J Ped Gastroenterol Nutr 2009; 48: 63–65.
18. Bauer MP, Notermans DW, van Benthem BH et al. Clostridium difﬁcile
infection in Europe: a hospital-based survey. Lancet 2011; 377: 63–73.
19. Kyne L, Warny M, Qamar A et al. Association between antibody
response to toxin A and protection against recurrent Clostridium difﬁ-
cile diarrhoea. Lancet 2001; 357: 189–193.
20. Hu MY, Katchar K, Kyne L et al. Prospective derivation and validation
of a clinical prediction rule for recurrent Clostridium difﬁcile infection.
Gastroenterology 2009; 136: 1206–1214.
21. Pe´pin J, Alary M-E, Valiquette L et al. Increasing risk of relapse after
treatment of Clostridium difﬁcile colitis in Quebec, Canada. Clin Infect
Dis 2005; 40: 1591–1597.
22. Babakhani F, Gomez A, Robert N et al. Killing kinetics of ﬁdaxomicin
and its major metabolite, OP-1118, against Clostridium difﬁcile. J Med
Microbiol 2011; 60: 1213–1217.
23. Louie TJ, Emery J, Krulicki W et al. OPT-80 Eliminates Clostridium dif-
ﬁcile and is sparing of Bacteroides species during treatment of C. difﬁ-
cile infection. Antimicrob Agents Chemother 2009; 53: 261–263.
24. Tannock GW, Munro K, Taylor C et al. A new macrocyclic antibiotic,
ﬁdaxomicin (OPT-80), causes less alteration to the bowel microbiota
of Clostridium difﬁcile-infected patients than does vancomycin. Microbi-
ology 2010; 156: 3354–3359.
25. Babakhani F, Gomez A, Robert N et al. Postantibiotic effect of ﬁdax-
omicin and its major metabolite, OP-1118, against Clostridium difﬁ-
cile. Antimicrob Agents Chemother 2011; 55: 4427–4429.
26. Mullane KM, Gorbach S. Fidaxomicin: ﬁrst-in-class macrocyclic antibi-
otic. Expert Rev Anti Infect Ther 2011; 9: 767–777.
27. Gerding DN. Is there a relationship between vancomycin-resistant
enterococcal infection and Clostridium difﬁcile infection? Clin Infect Dis
1997; 25 (Suppl 2): S206–S210.
28. European Medicines Agency. Committee for Medicinal Products for
Human Use (CHMP) Assessment report for DIFICLIR (ﬁdaxomicin),
22 September 2011; EMA/857570/2011. London, UK.
29. Shue YK, Sears PS, Shangle S et al. Safety, tolerance, and pharmacoki-
netic studies of OPT-80 in healthy volunteers following single and mul-
tiple oral doses. Antimicrob Agents Chemother 2008; 52: 1391–1395.
30. Cornely OA, Crook DW, Esposito R et al. Fidaxomicin versus vanco-
mycin for infection with Clostridium difﬁcile in Europe, Canada, and
the USA: a double-blind, non-inferiority, randomised controlled trial.
Lancet Infect Dis 2012; 12: 281–289.
31. Crook DW, Walker AS, Kean Y et al. Fidaxomicin versus vancomycin
for Clostridium difﬁcile infection: meta-analysis of pivotal randomized
controlled trials. Clin Infect Dis 2012; 55 (Suppl 2): S93–S103.
32. Petrella LA, Sambol SP, Cheknis A et al. Decreased cure rate and
increased recurrence rate for Clostridium difﬁcile infection caused by
the epidemic C. difﬁcile BI strain. Clin Infect Dis 2012; 55: 351–357.
33. Cornely OA, Miller M, Louie TA, Crook DW, Gorbach SL. Treat-
ment of ﬁrst recurrence of Clostridium difﬁcile infection: ﬁdaxomicin
versus vancomycin. Clin Infect Dis 2012; 55 (Suppl 2): S154–S161.
34. Mullane KM, Miller MA, Weiss K et al. Efﬁcacy of ﬁdaxomicin versus
vancomycin as therapy for Clostridium difﬁcile infection in patients tak-
ing concomitant antibiotics for other concurrent infections. Clin Infect
Dis 2011; 53: 440–447.
35. Cunney RJ, Magee C, McNamara E et al. Clostridium difﬁcile colitis
associated with chronic renal failure. Nephrol Dial Transplant 1998; 13:
2842–2846.
36. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during
oral and intravenous therapy for antibiotic associated colitis due to
Clostridium difﬁcile. Gut 1986; 27: 1169–1172.
37. Schroeder MS. Clostridium difﬁcile-associated diarrhea. Am Fam Physi-
cian 2005; 71: 921–928.
38. Brandt LJ, Aroniadis OC, Mellow M et al. Long-term follow-up of col-
onoscopic fecal microbiota transplant for recurrent Clostridium difﬁcile
infection. Am J Gastroenterol 2012; 107: 1079–1087.
39. Kyne L, Warny M, Qamar A, Kelly C. Asymptomatic carriage of Clos-
tridium difﬁcile and serum levels of IgG antibody against toxin A. N
Engl J Med 2000; 342: 390–397.
40. McFarland LV. Alternative treatment for Clostridium difﬁcile disease:
what really works? J Med Microbiol 2005; 54: 101–111.
CMI Cornely Fidaxomicin for the treatment of C. difﬁcile infection 35
ª2012 The Author
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18 (Suppl. 6), 28–35
